{"entity":{"id":"nct05280314","kind":"trial","name":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors","aka":[],"tldr":"A phase 2 trial of IO102-IO103 in melanoma, run by IO Biotech, now recruiting.","summary":"Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors is a phase 2 interventional study registered as NCT05280314 by IO Biotech, with 60 participants planned, started 2023-12-21 and due to reach its primary completion in 2025-04-30. Interventions recorded: IO102-IO103, Pembrolizumab KEYTRUDA®. Conditions listed: Melanoma, Squamous Cell Carcinoma of Head and Neck. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05280314","url":"https://clinicaltrials.gov/study/NCT05280314"}],"tags":["ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["io102-io103"],"companies":["io-biotech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05280314","phase":"2","setting":"Phase II, Multi-cohort Trial of Neoadjuvant and Post-surgery IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Selected Resectable Tumors","sponsor":"IO Biotech","enrolled":60,"outcomes":[]},"route":"/trials/nct05280314/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"io102-io103","kind":"drug","name":"IO102-IO103","route":"/drugs/io102-io103/"}],"company":[{"id":"io-biotech","kind":"company","name":"IO Biotech","route":"/companies/io-biotech/"}]}}